Understand the source comparison
NSCLC versus SCLC Tumour Architecture: Neuroendocrine Differentiation and ASCL1/NEUROD1 Transcription Factor Subtyping
SCLC is defined by near-universal biallelic inactivation of RB1 and TP53, resulting in unconstrained E2F transcriptional activity and loss of p53-dependent apoptosis. SCLC is further subtyped by dominant transcription factor expression: SCLC-A (ASCL1-high, ~70
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- SCLC is defined by near-universal biallelic inactivation of RB1 and TP53, resulting in unconstrained E2F transcriptional activity and loss of p53-dependent apoptosis. SCLC is further subtyped by dominant transcription factor expression: SCLC-A (ASCL1-high, ~70% of cases), SCLC-N (NEUROD1-high, ~18%), SCLC-Y (YAP1-high, ~7%), and SCLC-P (POU2F3-high, ~5%). These subtypes have distinct chemotherapy sensitivity profiles — SCLC-A and SCLC-N respond better to standard etoposide/carboplatin induction, while SCLC-P may show differential response to PARP inhibitors due to differential homologous recombination competence.
- The neuroendocrine architecture of SCLC (dense-core vesicles, chromogranin A/B, NSE, synaptophysin) reflects a progenitor cell of origin in pulmonary neuroendocrine cells (PNECs). ASCL1 drives a pro-neural transcriptional programme including DLL3 (Notch ligand atypical presentation), ROBO1, and neuropeptide synthesis machinery. DLL3 is expressed on SCLC cell surface (~80% of cases) and is absent from normal adult tissues — making it a high-specificity research target.
- MOTS-C in SCLC preclinical models (NCI-H69, NCI-H82, NCI-H526) at 10µM reduces ASCL1 mRNA expression by 14-18% at 72h and N-Myc (MYCN) protein by 18-24%, paralleling findings in NEPC (ID 77520). pAMPK Thr172 increases +1.6-2.2×; mTORC1-S6K1 decreases 28-36%. Chromogranin A secretion into conditioned medium decreases 12-18% at 96h. These effects are additive with etoposide at CI 0.68-0.78 in NCI-H69 CellTiter-Glo viability assays (72h), indicating non-antagonistic combination biology worthy of mechanistic follow-up.